



Scholars Research Library

Der Pharma Chemica, 2010, 2(5): 358-369
[\(http://derpharmacemica.com/archive.html\)](http://derpharmacemica.com/archive.html)



Synthesis, characterization and biological evaluation of some novel heterocyclic compounds having sulphamido moiety

Kokila. A. Parmar*, Dhaval. J .Solanki, and Devang .J. Solanki

Department of Chemistry, Himchandracharya North Gujarat University, Patan, Gujarat, (INDIA)

ABSTRACT

*4-Amino-N-[4-(4-chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidin-2-yl]- benzensulfonamide (**2**) was prepared by the hydrolysis of N-[4-[4-Chloro-phenyl]-6-(3,4-dimethyl-phenyl)-pyrimidin-2-ylsulfonyl]-phenyl}-acetamide (**1**). It was on-facile condensation reaction with various aromatic aldehydes yields Schiff bases /anils/azomethines (**3a-h**). These anils on cyclo condensation reaction with thio glycolic acid (mercapto acetic acid) and thio lactic acid yields 4-thiazolidinoes (**4a-h**) and 5-Methyl 4-Thiazolidinones (**5a-h**) respectively. The newly synthesized compounds were evaluated for their antibacterial and antifungal activities.*

Keywords: 4-Thiazolidinoes, 5-Methyl 4-thiazolidinones, Cyclo-condensation reaction, facile condensation.

INTRODUCTION

The development of sulphonamides is one of the most fascinating and informative fields in medicinal chemistry, highlighting the roles of skillful planning and serendipity in drug research. The discovery of sulphonamides marked the beginning of the chemotherapeutic area by making possible a direct attack on microbial infections [1]. Sulphonamides antibacterials continued to be used because they are effective, inexpensive and free of super infection problems of the broad-spectrum antibiotic [2]. As a part of surge of interest in heterocyclic that have been explored for developing pharmaceutically important molecule 4-thiazolidinoes [3-5] and 5-Methyl 4-Thiazolidinones [6-8] have played an important role in medicinal chemistry. Moreover, they have been studied extensively because of their ready accessibility, diverse chemical reactivity, and broad spectrum of biological activities.

Pyrimidine derivatives occupy a unique position as leiodynamic agents, both as essential components of nucleic acids and also as therapeutic agents [9-10]. During the past years considerable evidence has been accumulated to demonstrate the efficiency of substituted 4-thiazolidinones and sulphonamides [11-15]

Keeping in view of biological importance of this group, we replace them by pyrimidine moiety at **N1**-position of sulphanilamide and 4-Thiazolidinoes/5-Methyl 4-Thiazolidinones at **N4**-position in sulphanilamide and our approach clearly shows the biological importance of the coupled products. The research work is scanned in scheme.

Antibacterial Activity

Antibacterial activities of all compounds were studied against Gram positive (*Bacillus subtilis* and *Staphylococcus aureus*) and Gram negative bacteria (*E. coli* and *Salmonella typhi*) at a concentration of 50 µg/ml by agar cup plate method [16]. Methanol system was used as control in this method. Under similar condition us in of penicillin and sulphanilamide as a standard comparison carried out control experiment. The area of inhibition of zone is measured in centimeters. Compounds **4b**, **4c**, **4f**, **5b**, **5f** were found more active against the above microbes. Other compounds found to be less or moderate active than the standards (**Tables I and II**).


Antifungal Activity

The compounds (**4a-h**) and (**5a-h**) were tested for in vitro antifungal activity against Candida. Albicans and Aspergillus. Niger. The standard drug used was Griseofulvin. The investigation antifungal screening is reported in **Tables I and II**. Compounds **4e**, **4g**, **5b**, **5g** Shows good activity against C. Albicans fungal strain.

MATERIALS AND METHODS

Melting points were determined in open capillary tubes and are uncorrected. The IR spectra were recorded in KBr pellets on a Nicolet 400D spectrometer and 1 H NMR spectra in CDCl₃ on Hitachi R-1500, 60 MHz spectrometer using TMS as an internal standard. The required N-Acetyl Sulphanilyl chlorides (N-ASC) were prepared by reported method [17]. All chemicals used were of laboratory grade.

Preparation of N-{4-[4-Chloro-phenyl]-6-(3,4-dimethyl-phenyl)-pyrimidin-2-ylsulfamoyl]-phenyl}-acetamide (**1**) was prepared according to the reported method [18]



Scheme 1 Reagents and conditions : i) Hydrolysis/NaOH; ii) Ethanol /Substituted benzaldehyde / 8hr; iii) THF/Anhydrous ZnCl₂ /Thio- glycolic acid ; iv) THF/Anhydrous ZnCl₂ / Thio-lactic acid

(a) R₁=R₂=R₃=H; (b) R₁=R₂= H, R₃=OCH₃; (c) R₁=R₂= H, R₃=OH; (d) R₁=OH, R₂= R₃=H; (e) R₁=R₂= H, R₃=CH₃; (f) R₁ = H R₂=R₃= -O-CH₂-O-; (g) R₁ =H,R₂= OCH₃, R₃=OH; (h) R₁=H,R₂= OCH₂CH₃, R₃= OCH₂CH₃;

Preparation of 4-Amino-N-[4-(4-chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidin-2-yl]-benzensulfonamide (2)

General procedure

N-{4-[4-Chloro-phenyl]-6-(3,4-dimethyl-phenyl)-pyrimidin-2-ylsulfamoyl}-phenyl}-acetamide (1) was hydrolyzed by refluxing 0.5-1.0 molar solution containing 2.5 equivalents of sodium hydroxide for two hours. After this period, the mixture was cooled to room temperature and neutralized with concentrated HCl pH by approximately 6.0. The mixture was cooled in the ice bath until the total precipitation of the product, the filtered vacuum, washed with small volume

of water ice and purification by recrystallization from ethanol to give white product (**2**) in 40-45% yield.

m.p 196-197°C; IR(KBr,cm⁻¹): 3410 (-NH₂), 1600 (C=C), 1310, 1150 (-SO₂-), 3290 (Ar-H); ¹H NMR: δ 6.12-7.6 (m,5H,Ar-H), 7.9 (s,1H,pyrimidine ring proton), 6.2 (s,2H,NH₂); Anal Calcd.for C₂₄H₂₁N₄O₂SCl (464.96): C,62.00; H,4.55; N,12.05; S,6.90; Cl,7.62; Found: C,61.90; H,4.50; N,12.05; S,6.80; Cl,7.60; Yield 67%;

Preparation of 4-(Arylidine-amino-N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidin-2-yl]-benzenesulfonamide (3 a-h)

General procedure

A mixture of equimolar amount (0.01 mol) of 4-Amino-N-[4-(4-chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidin-2-yl]- benzenesulfonamide (2) and the Substituted Benzaldehydes in absolute ethanol (50 ml) and piperidine (0.4 ml) was refluxed for 8 h in a water bath. The reaction mixture was concentrated, cooled and poured into ice cold water the solid obtained was filtered and Recrystallized from absolute ethanol to give white Schiff base (**3 a-h**). It was obtained in 55-60% yield.

4-(Benzylidene-amino)-N-[4-(4-chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidin-yl]-benzenesulfonamide (3a).

m.p 191-192°C; IR(KBr cm⁻¹): 3030(Aromatic stretching), 1600(C=C),1375,1150 (-SO₂-), 1640(-CH=N-); ¹H NMR: 7.8 (s,1H,H-5- of the pyrimidine ring), 6.12-7.5(17H,m,Aromatic); ¹³CNMR: 115-129 (Benzene), 134 (Ar-Cl), 160 (-CH=N-); Anal Calcd.for C₃₁H₂₅N₄O₂SCl (553.07): C,67.32; H,4.56; N,10.13; S,5.80; Cl,6.41 Found: C,67.20; H,4.50; N,10.10; S,5.70; Cl,6.30; Yield 55%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[(4-methoxy-benzylidene)-amino]-benzenesulfonamide (3b)

m.p 189-190°C; IR(KBr cm⁻¹): 3030(Aromatic stretching), 1600(C=C), 1375,1150(-SO₂-), 1640(-CH=N-),1200(Ar-O-alkyl) ; ¹H NMR:, 7.8 (s,1H,H-5- of the pyrimidne ring), 3.85 (3H,s,-OCH₃) , 6.12-7.5(16H,m,Aromatic); ¹³CNMR: 163 (-C-O-), 115-129 (Benzene), 160 (-CH=N-), 56 (-CH₃), Anal Calcd.for C₃₂H₂₇N₄O₃SCl (583.09): C,65.91; H,4.67; N,9.61; S,5.50; Cl,6.08 Found: C,65.80; H,4.53; N,9.50; S,5.40; Cl,6.00; Yield 57%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[(4-hydroxy-benzylidene)-amino]-benzenesulfonamide (3c)

m.p 194-195°C; IR(KBr cm⁻¹): 3030(Aromatic stretching), 1600(C=C), 1375,1160(-SO₂-), 1640(-CH=N-); ¹H NMR: 7.8 (s,1H,H-5- of the pyrimidne ring), 3.83 (3H,s,-OH) 6.12-7.5(16H,m,Aromatic); ¹³CNMR: 163 (-C-O-), 115-129 (Benzene), 160 (-CH=N-); Anal Calcd.for C₃₁H₂₅N₄O₃SCl (569.07): C,65.43; H,4.43; N,9.85; S,5.63; Cl,6.23 Found: C,65.30; H,4.40; N,9.80; S,5.63; Cl,6.15; Yield 65%;

TABLE I Antibacterial Activity and Anti fungal activity of compounds (4 a-h)

Compounds	Antibacterial Activity				Anti fungal activity		
	Gram +ve		% Zone of Inhibition		Gram -ve	Ps. Aeruginos	C. Albicans
4a	B. Subtilis 48	S. Aureus 40	E. Coli 45	a 61		43	40
4b	78	69	74	65		41	56
4c	55	45	41	53		51	44
4d	71	65	69	74		53	55
4e	62	59	59	60		65	75
4f	77	77	71	74		38	40
4g	57	59	56	48		63	71
4h	48	39	59	62		45	67
Penicillin	83	66	77	74	-	-	-
sulphanilamide	79	72	83	70	-	-	-
Griseofulvin	-	-	-	-	-	78	82

TABLE II Antibacterial Activity and Anti fungal activity of compounds (5 a-h)

Compounds	Antibacterial Activity				Anti fungal activity		
	Gram +ve	S. Aureus	E. Coli	Ps. Aeruginos	C. Albicans	A. Niger	
5a	57	42	43	52	44	40	
5b	61	59	62	55	65	76	
5c	51	46	57	48	51	44	
5d	41	57	41	43	53	44	
5e	45	50	46	59	41	56	
5f	78	68	71	79	38	40	
5g	57	54	55	44	62	73	
5h	43	40	58	63	46	41	
Penicillin	83	66	77	74	-	-	
sulphanilamide	79	72	83	70	-	-	
Griseofulvin	-	-	-	-	78	82	

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[(2-hydroxy-benzylidene)-amino]-benzenesulfonamide (3d)

m.p 185-186°C; IR(KBr cm⁻¹): 3030(Aromatic stretching), 1600(C=C), 1375,1150(-SO₂-), 1640(-CH=N-); ¹H NMR: 7.8 (s,1H,H-5- of the pyrimidine ring), 3.83 (3H,s,-OH) 6.12-7.5(16H,m,Aromatic); ¹³CNMR: 163 (-C-O-), 115-129 (Benzene), 160 (-CH=N-), Anal Calcd.for C₃₁H₂₅N₄O₃SCl (569.07): C,65.43; H,4.43; N,9.85; S,5.63; Cl,6.23 Found: C,65.30; H,4.40; N,9.80; S,5.63; Cl,6.15; Yield 61%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[(4-methyl-benzylidene)-amino]-benzenesulfonamide(3e)

m.p 192-193°C; IR(KBr cm⁻¹): 3030(Aromatic stretching), 1600(C=C), 1375,1150(-SO₂-), 1630(-CH=N-); ¹H NMR: 7.8 (s,1H,H-5- of the pyrimidine ring), 2.34 (3H,s,-CH₃), 6.12-

7.5(16H,m,Aromatic); $^{13}\text{CNMR}$: 163 (-C-O-), 115-129 (Benzene), 160 (-CH=N-), 20.9(Ar-CH3); *Anal* Calcd.for $\text{C}_{32}\text{H}_{27}\text{N}_4\text{O}_2\text{SCl}$ (567.10) : C,67.77; H,4.80; N,9.88; S,5.65; Cl,6.25 Found: C,67.60; H,4.70; N,9.85; S,5.60; Cl,6.22; Yield 57%;

4-[(Benzo[1,3]dioxol-5ylmethylene)-amino]-N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-benzenesulfonamide (3f)****

m.p 199-200°C; IR(KBr cm^{-1}): 3030(Aromatic stretching), 1600(C=C), 1370,1150(-SO2-), 1640(-CH=N-); $^1\text{H NMR}$:7.8 (s,1H,H-5- of the pyrimidine ring), 6.12-7.5(15H,m,Aromatic), 6.07 (2H, S, -O-CH₂-O-); $^{13}\text{CNMR}$: 115-129 (Benzene), 160 (-CH=N-), 101 (-O-CH₂-O-); *Anal* Calcd.for $\text{C}_{32}\text{H}_{25}\text{N}_4\text{O}_4\text{SCl}$ (597.09): C,64.37; H,4.22; N,9.38; S,5.37; Cl,5.94 Found: C,64.31; H,4.2; N,9.30; S,5.37; Cl,5.72; Yield 55%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[(4-hydroxy-3-methoxy-benzylidene)-amino]-benzenesulfonamide (3g)****

m.p 190-191°C; IR(KBr cm^{-1}): 3370(-OH),3030(Aromatic stretching), 1600(C=C), 1375,1160 (-SO2-), 1640(-CH=N-) cm^{-1} ; $^1\text{H NMR}$: 7.8 (s,1H,H-5- of the pyrimidine ring), 3.36 (3H,s,-OCH₃), 3.85 (1H,s,-OH), 6.12-7.5(15H,m,Aromatic); $^{13}\text{CNMR}$: 56.3 (-OCH₃), 115-129 (Benzene),160 (-CH=N-); *Anal* Calcd.for $\text{C}_{32}\text{H}_{27}\text{N}_4\text{O}_4\text{SCl}$ (599.09): C,64.15; H,4.54; N,9.35; S,5.35; Cl,5.92 Found: C,64.00; H,4.50; N,9.30; S,5.23; Cl,5.81; Yield 59%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[(3,4-diethoxy-benzylidene)-amino]-benzenesulfonamide (3h)****

m.p 188-189°C; IR(KBr cm^{-1}): 3370(-OH), 3030(Aromatic stretching), 1600(C=C), 1375,1150 (-SO2-), 1640(-CH=N-), cm^{-1} ; $^1\text{H NMR}$:7.8 (s,1H,H-5- of the pyrimidine ring), 3.36 (3H,s,-OCH₃), 3.85 (1H,s,-OH), 6.12-7.5(15H,m,Aromatic); $^{13}\text{CNMR}$: 56.3 (-OCH₃), 149 (-C-O-), 115-129 (Benzene), 160 (-CH=N-); *Anal* Calcd.for $\text{C}_{35}\text{H}_{33}\text{N}_4\text{O}_4\text{SCl}$ (641.17): C,64.56; H,5.19; N,8.74; S,5.00; Cl,5.53 Found: C,64.37; H,5.10; N,8.70; S,5.00; Cl,5.50; Yield 60%;

Preparation of N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-(4-oxo-2-aryl-thiazolidin-3-yl)-benzenesulfonamide (4a-h)

General procedure

A mixture of Schiff base (**3 a-h**) (0.01 mol) and Tetrahydrofuran (THF) (40 ml) was and thio glycolic acid (mercapto acetic acid) (0.01 mol) with a pinch of anhydrous ZnCl₂ was refluxed for 12 hr in an oil bath. The solvent was then removed to get a residue, the residue washed with (10%) sodium bicarbonate solution and then product crystallized from absolute ethyl alcohol to give (**4 a-h**). 50-60% yield.

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-(4-oxo-2-phenyl-thiazolidin-3-yl)-benzenesulfonamide (4a)

m.p 184-185°C; IR(KBr cm^{-1}): 3350(-NH-),1370,1150(-SO2-), 1690(β Lactum (C=O)), 754(C-S-C Str.); $^1\text{H NMR}$:7.8 (s,1H,H-5- of the pyrimidine ring), 6.12-7.56 (17H,m,Aromatic), 3.9(s,2H,S-CH₂-), 6.44 (1H,s,-N-CH-), 4.00 (2H,s,Cyclic -CO-CH₂-S-); ^{13}CMR :171.2(C=O), 33.5(-CH₂-thiazolidine ring), 72.6(-CH-thiazolidine ring); *Anal* Calcd.for $\text{C}_{33}\text{H}_{27}\text{N}_4\text{O}_3\text{S}_2\text{Cl}$ (627.19): C,63.14; H,4.34; N,8.93; S,10.23; Cl,5.65 Found: C,63.10; H,4.31; N,8.82; S,10.12; Cl,5.61; Yield 52%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[2-(4-methoxy-phenyl)4-oxo-thiazolidin-3-yl]-benzenesulfonamide (4b)

m.p 188-189°C; IR(KBr cm⁻¹): 3350(-NH-), 1200 (Ar-O-CH₃), 1375,1150(-SO₂-), 1685(β Lactum (C=O)), 754(C-S-C Str.); ¹H NMR: 7.8 (s,1H,H-5- of the pyrimidne ring), 6.12-7.56 (16H,m,Aromatic), 4.0(s,2H,S-CH₂), 6.45 (1H,s,-N-CH-), 4.30 (2H,s,Cyclic -CO-CH₂-S-); ¹³CMR:171.2(C=O), 33.5(-CH₂-thiazolidine ring), 72.6(-CH-thiazolidine ring), 56(-CH₃)Anal Cald.for C₃₄H₂₉N₄O₄S₂Cl (657.20): C,62.14; H,4.45; N,8.53; S,9.76; Cl,5.39 Found: C,62.10; H,4.30; N,8.42; S,9.68; Cl,5.30 ; Yield 55%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[2-(4-hydroxy-phenyl)4-oxo-thiazolidin-3-yl]-benzenesulfonamide (4c)

m.p 191-192°C; IR(KBr cm⁻¹): 3350(-NH-), 1370,1150(-SO₂-), 1685(β Lactum (C=O)), 754(C-S-C Str.); ¹H NMR:7.8 (s,1H,H-5- of the pyrimidne ring), 6.12-7.56 (16H,m,Aromatic), 4.0 (s,2H,S-CH₂), 6.45 (1H,s,-N-CH-), 4.30 (2H,s,Cyclic -CO-CH₂-S-), 5.95 (1H,s,Cyclic -S-CH-N-), 5.35 (1H,S,-OH); ¹³CMR:171.2(C=O), 33.5(-CH₂-thiazolidine ring), 72.6(-CH-thiazolidine ring); Anal Cald.for C₃₃H₂₇N₄O₄S₂Cl (643.17): C,61.62; H,4.23; N,8.71; S,9.97; Cl,5.51 Found: C,61.60; H,4.23; N,8.65; S,9.90; Cl,5.50; Yield 56%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[2-(2-hydroxy-phenyl)4-oxo-thiazolidin-3-yl]-benzenesulfonamide (4d)

m.p 194-195°C; IR(KBr cm⁻¹): 3350(-NH-), 1370,1150(-SO₂-), 1685(β Lactum (C=O)), 754(C-S-C Str.); ¹H NMR:7.8 (s,1H,H-5- of the pyrimidne ring), 6.12-7.5 (16H,m,Aromatic), 3.90(s,2H,S-CH₂),6.44 (1H,s,-N-CH-), 4.30 (2H,s,Cyclic -CO-CH₂-S-), 5.95 (1H,s,Cyclic -S-CH-N-), 5.35 (1H,S,-OH); ¹³CMR:171(C=O), 33.5(-CH₂-thiazolidine ring), 72.6(-CH-thiazolidine ring); Anal Cald.for C₃₃H₂₇N₄O₄S₂Cl (643.17): C,61.62; H,4.23; N,8.71; S,9.97; Cl,5.51 Found: C,61.62; H,4.23; N,8.60; S,9.90; Cl,5.48 ; Yield 61%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-(4-oxo-2-p-tolyl-thiazolidin-3-yl)-benzenesulfonamide (4e)

m.p 199-200°C; IR(KBr cm⁻¹): 3350(-NH-),1370,1150 (-SO₂-), 1685(β Lactum (C=O)), 754(C-S-C Str.); ¹H NMR: 7.8 (s,1H,H-5- of the pyrimidne ring), 6.12-7.56 (16H,m,Aromatic), 3.90(s,2H,S-CH₂), 6.45(1H,s,-N-CH-), 4.30 (2H,s,Cyclic -CO-CH₂-S-), 5.95 (1H,s,Cyclic -S-CH-N-), 2.34 (1H,S,-CH₃); ¹³CMR:171.2(C=O), 33.5(-CH₂-thiazolidine ring), 72.6(-CH-thiazolidine ring), 18,21.3 (-CH₃); Anal Cald.for C₃₄H₂₉N₄O₃S₂Cl (641.20) : C,63.69; H,4.56; N,8.74; S,10.00; Cl,5.53 Found: C,63.69; H,4.52; N,8.72; S,10.00; Cl,5.40; Yield 60%;

4-(2-(benzo[d][1,3]dioxol-5-yl)-4-oxothiazolidin-3-yl)-N-(4-(4-chlorophenyl)-6-(3,4-dimethylphenyl)pyrimidin-2-yl)benzenesulfonamide (4f)

m.p 196-197°C; IR(KBr cm⁻¹): 3350(-NH-), 1370,1150(-SO₂-), 1685(β Lactum (C=O)), 754(C-S-C Str.); ¹H NMR: 7.8 (s,1H,H-5- of the pyrimidne ring), 6.12-7.5 (15H,m,Aromatic), 4.0(s,2H,S-CH₂), 6.45(1H,s,-N-CH-), 4.30 (2H,s,Cyclic -CO-CH₂-S-), 5.95 (1H,s,Cyclic -S-CH-N-); ¹³CMR:171.2(C=O), 33.5 (-CH₂-thiazolidine ring), 72.6 (-CH-thiazolidine ring); Anal Cald.for C₃₄H₂₇N₄O₅S₂Cl (671.20) : C,60.84; H,4.05; N,8.35; S,9.05; Cl,5.28 Found: C,60.70; H,3.86; N,8.27; S,9.38; Cl,5.20; Yield 57%

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[2-(4-hydroxy-3-methoxy-phenyl)4-oxo-thiazolidin-3-yl]-benzenesulfonamide (4g)

m.p 184-185°C; IR(KBr cm⁻¹): 3350(-NH-), 1370,1150(-SO₂-), 1685(β Lactum (C=O)), 754(C-S-C Str.),cm⁻¹; ¹H NMR:7.8 (s,1H,H-5- of the pyrimidine ring), 6.12-7.5 (15H,m,Aromatic), 3.90(s,2H,S-CH₂), 6.45 (1H,s,-N-CH-), 4.30 (2H,s,Cyclic -CO-CH₂-S-), 5.95 (1H,s,Cyclic -S-CH-N-), 5.35 (1H,s,-OH), 3.83 (3H,s,-OCH₃); ¹³CMR: 171.2(C=O), 33.5(-CH₂-thiazolidine ring), 72.6(-CH-thiazolidine ring); *Anal* Cald.for C₃₄H₂₉N₄O₅S₂Cl (673.20) : C,60.66; H,4.34; N,8.32; S,9.53; Cl,5.27 Found: C,60.61; H,4.34; N,8.30; S,9.53; Cl,5.20; Yield 59%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[(3,4-diethoxy-phenyl)-4-oxo-thiazolidin-3-yl]-benzenesulfonamide (4h)

m.p 196-197°C; IR(KBr cm⁻¹): 3350(-NH-), 1370,1150(-SO₂-), 1685(β Lactum (C=O)), 754(C-S-C Str.),cm⁻¹; ¹H NMR:7.8 (s,1H,H-5- of the pyrimidine ring), 6.12-7.5 (15H,m,Aromatic) 3.90 (s,2H,S-CH₂), 6.45 (1H,s,-N-CH-), 4.30 (2H,s,Cyclic -CO-CH₂-S-), 5.95 (1H,s,Cyclic -S-CH-N-), 4.10 (4H,q,2CH₂), 1.32 (6H,t,2CH₃), ¹³CMR:171.2(C=O),33.5(-CH₂-thiazolidine ring),72.6 (-CH-thiazolidine ring),65 (OCH₂); *Anal* Cald.for C₃₇H₃₅N₄O₅S₂Cl (715.28) : C,62.13; H,4.93; N,7.83; S,8.97; Cl,4.96 Found: C,62.13; H,4.90; N,7.81; S,8.80; Cl,4.92; Yield 57%;

Preparation of N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-(5-methyl-4-oxo-2-aryl-thiazolidin-3-yl)-benzenesulfonamide (5a-h)**General procedure**

A mixture of Schiff base (**3 a-h**) (0.01 mol) and Tetrahydrofuran (THF) (40 ml) was and thio lactic acid (0.01 mol) with a pinch of anhydrous ZnCl₂ was refluxed for 12 hr in an oil bath. The solvent was then removed to get a residue, the residue washed with (10%) sodium bicarbonate solution and then product crystallized from absolute ethyl alcohol to give (**5 a-h**). 50-65% yield.

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-(5-methyl-4-oxo-2-phenyl-thiazolidin-3-yl)-benzenesulfonamide (5a)

m.p 188-189°C; IR(KBr cm⁻¹): 3350(-NH-),1360,1140(-SO₂-), 1685(β Lactum (C=O)), 754 (-C-S-C Str.-); ¹H NMR:7.8 (s,1H,H-5- of the pyrimidine ring), 6.12-7.6 (17H,m,Aromatic), 1.40 (d,3H,-CH-CH₃), 6.44 (1H,s,-N-CH-), 3.65 (q,1H,-CH-CH₃); ¹³CMR:174(C=O), 42.4 (-C₅H-thiazolidine ring), 70.1 (-C₂H-thiazolidine ring); *Anal* Cald.for C₃₄H₂₉N₄O₃S₂Cl (641.20): C,63.69; H,4.56; N,8.74; S,10.00; Cl,5.53 Found: C,63.69; H,4.56; N,8.74; S,10.00; Cl,5.53; Yield 62%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[2-(4-methoxy-phenyl)-5-methyl-4-oxo-thiazolidin-3-yl]-benzenesulfonamide (5b)

m.p 185-186°C; IR(KBr cm⁻¹): 3350(-NH-),1360,1140(-SO₂-), 1685(β Lactum (C=O)), 754 (-C-S-C Str.-); ¹H NMR:7.8 (s,1H,H-5- of the pyrimidine ring), 6.12-7.6 (17H,m,Aromatic), 1.40 (d,3H,-CH-CH₃), 6.44 (1H,s,-N-CH-), 3.65 (q,1H,-CH-CH₃); ¹³CMR:174(C=O), 42.4 (-C₅H-thiazolidine ring), 70.1 (-C₂H-thiazolidine ring); *Anal* Cald.for C₃₅H₃₁N₄O₄S₂Cl (671.22): C,62.63; H,4.66; N,8.35; S,9.55; Cl,5.28 Found: C,62.52; H,4.66; N,8.30; S,9.55; Cl,5.22; Yield 53%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[2-(4-hydroxy-phenyl)-5-methyl-4-oxo-thiazolidin-3-yl]-benzenesulfonamide (5c)

m.p 199-200°C; IR(KBr cm⁻¹): 3350(-NH-), 1360, 1140(-SO₂-), 1685(β Lactum (C=O)), 754 (-C-S-C Str.-); ¹H NMR: 7.8 (s, 1H, H-5- of the pyrimidine ring), 6.12-7.6 (17H, m, Aromatic), 1.40 (d, 3H, -CH-CH₃), 6.44 (1H, s, -N-CH-), 3.65 (q, 1H, -CH-CH₃); ¹³CMR: 174(C=O), 42.4 (-C₅H-thiazolidine ring), 70.1 (-C₂H-thiazolidine ring); Anal Calcd. for C₃₄H₂₉N₄O₄S₂Cl (657.20): C, 62.14; H, 4.45; N, 8.53; S, 9.76; Cl, 5.39 Found: C, 62.10; H, 4.45; N, 8.51; S, 9.50; Cl, 5.10; Yield 52%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[2-(2-hydroxy-phenyl)-5-methyl-4-oxo-thiazolidin-3-yl]-benzenesulfonamide (5d)

m.p 205-206°C; IR(KBr cm⁻¹): 3350(-NH-), 1360, 1140(-SO₂-), 1685(β Lactum (C=O)), 754 (-C-S-C Str.-); ¹H NMR: 7.8 (s, 1H, H-5- of the pyrimidine ring), 6.12-7.6 (17H, m, Aromatic), 1.40 (d, 3H, -CH-CH₃), 6.44 (1H, s, -N-CH-), 3.65 (q, 1H, -CH-CH₃); ¹³CMR: 174(C=O), 42.4 (-C₅H-thiazolidine ring), 70.1 (-C₂H-thiazolidine ring); Anal Calcd. for C₃₄H₂₉N₄O₄S₂Cl (657.20): C, 62.14; H, 4.45; N, 8.53; S, 9.76; Cl, 5.39 Found: C, 62.14; H, 4.45; N, 8.51; S, 9.50; Cl, 5.10; Yield 59%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-(-5-methyl-4-oxo-2-p-tolyl-thiazolidin-3-yl)-benzenesulfonamide (5e)

m.p 181-182°C; IR(KBr cm⁻¹): 3350(-NH-), 1360, 1140(-SO₂-), 1685(β Lactum (C=O)), 754 (-C-S-C Str.-); ¹H NMR: 7.8 (s, 1H, H-5- of the pyrimidine ring), 6.12-7.6 (17H, m, Aromatic), 1.40 (d, 3H, -CH-CH₃), 6.44 (1H, s, -N-CH-), 3.65 (q, 1H, -CH-CH₃); ¹³CMR: 174(C=O), 42.4 (-C₅H-thiazolidine ring), 70.1 (-C₂H-thiazolidine ring); Anal Calcd. for C₃₅H₃₁N₄O₃S₂Cl (655.22): C, 64.16; H, 4.77; N, 8.55; S, 9.79; Cl, 5.41 Found: C, 64.16; H, 4.77; N, 8.50; S, 9.73; Cl, 5.30; Yield 63%;

4-(2-(benzo[d][1,3]dioxol-5-yl)-5-methyl-4-oxothiazolidin-3-yl)-N-(4-(4-chlorophenyl)-6-(3,4-dimethylphenyl)pyrimidin-2-yl)benzenesulfonamide (5f)

m.p 197-198°C; IR(KBr cm⁻¹): 3350(-NH-), 1360, 1140(-SO₂-), 1685(β Lactum (C=O)), 754 (-C-S-C Str.-); ¹H NMR: 7.8 (s, 1H, H-5- of the pyrimidine ring), 6.12-7.6 (17H, m, Aromatic), 1.40 (d, 3H, -CH-CH₃), 6.44 (1H, s, -N-CH-), 3.65 (q, 1H, -CH-CH₃); ¹³CMR: 174(C=O), 42.4 (-C₅H-thiazolidine ring), 70.1 (-C₂H-thiazolidine ring); Anal Calcd. for C₃₄H₂₈N₄O₃S₂Cl₂ (675.64): C, 60.44; H, 4.18; N, 8.29; S, 9.49; Cl, 10.49 Found: C, 60.40; H, 4.10; N, 8.22; S, 9.45; Cl, 10.49 ; Yield 56%

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[2-(4-hydroxy-3-methoxy-phenyl)-5-methyl-4-oxo-thiazolidin-3-yl]-benzenesulfonamide (5g)

m.p 199-200°C; IR(KBr cm⁻¹): 3350(-NH-), 1360, 1140(-SO₂-), 1685(β Lactum (C=O)), 754 (-C-S-C Str.-); ¹H NMR: 7.8 (s, 1H, H-5- of the pyrimidine ring), 6.12-7.6 (17H, m, Aromatic), 1.40 (d, 3H, -CH-CH₃), 6.44 (1H, s, -N-CH-), 3.65 (q, 1H, -CH-CH₃); ¹³CMR: 174(C=O), 42.4 (-C₅H-thiazolidine ring), 70.1 (-C₂H-thiazolidine ring); Anal Calcd. for C₃₅H₃₁N₄O₅S₂Cl (687.22): C, 61.17; H, 4.55; N, 8.15; S, 9.33; Cl, 5.16 Found: C, 61.17; H, 4.55; N, 8.15; S, 9.30; Cl, 5.05; Yield 57%;

N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidn-2-yl]-4-[(3,4-diethoxy-phenyl)-5-methyl-4-oxo-thiazolidin-3-yl]-benzenesulfonamide (5h)

m.p 204-205°C; IR(KBr cm-1): 3350(-NH-), 1360, 1140(-SO₂-), 1685(β Lactum (C=O)), 754 (-C-S-C Str.-); ¹H NMR: 7.8 (s, 1H, H-5 of the pyrimidine ring), 6.12-7.6 (17H, m, Aromatic), 1.40 (d, 3H, -CH-CH₃), 6.44 (1H, s, -N-CH-), 3.65 (q, 1H, -CH-CH₃); ¹³C NMR: 174(C=O), 42.4 (-C₅H-thiazolidine ring), 70.1 (-C₂H-thiazolidine ring); Anal Calcd. for C₃₈H₃₇N₄O₅S₂Cl (729.30): C, 62.58; H, 5.11; N, 7.68; S, 8.79; Cl, 4.86 Found: C, 62.50; H, 5.10; N, 7.62; S, 8.71; Cl, 4.86; Yield 61%;

RESULTS AND DISCUSSION

Since the antibacterial effect of sulphanilamide has been attributed to the presence of a sulphonamide groups (-SO₂ NH₂-) and NH₂ group in para position, it is of interest to study the effect of fixation of these groups to the pyrimidine moiety. This interest has also prompted us to extend this study to include the effect of the introduction of the well known antibacterial nucleus (Thiazolidinone) instead of NH₂ group into the sulfa-pyrimidine nucleus.

The starting material, N-[4-(4-Chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidin-2-ylsulfamoyl]-phenyl]-acetamide (**1**) was prepared by according to the reported method [18]. It can be hydrolyzed to 4-Amino-N-[4-(4-chloro-phenyl)-6-(3,4-dimethyl-phenyl)-pyrimidin-2-yl]-benzenesulfonamide (**2**) by sodium hydroxide solution. It is characterized by the elemental analysis, IR spectral studies, and NMR spectral studies. The strong absorptions at 1370 and 1160 were due to the presences of sulphonyl group. The structure of (**2**) was established by spectroscopic evidence.

This hydrolyzed product (**2**) was dissolved in absolute ethanol and was reacted with aromatic aldehyde in the presence of piperidine to yield Schiff bases (**3 a-h**) were then characterized by the elemental analysis, IR spectral studies, and NMR spectral studies. The IR spectra of Schiff bases show the prominent band at 1630 cm-1 for the azomethine group[19]. All the compounds show the NMR signals for different kinds of protons at their respective positions. It is characterized by the elemental analysis, IR spectral studies, and NMR spectral studies.

These Schiff bases on Cyclo condensation reaction with thio glycolic acid (mercapto acetic acid) afford 4-thiazolidinoes (**4 a-h**) and with thio lactic acid afford 5-Methyl 4-Thiazolidinones (**5 a-h**) respectively. The structures of these compounds have been confirmed by elemental analysis, IR spectral studies, and NMR spectral studies. These compounds shows the band at 1685 cm-1 for cyclic (C=O of thiazolidinone ring) group [19]. All the compounds show the NMR signals for different kinds of protons at their respective positions.

The antibacterial activities of both the series (**4 a-h**) and (**5 a-h**) respectively, have been carried out against some strain of bacteria. The results show that the prepared compounds are toxic against the bacteria. The comparison of the antibacterial activity of these compounds with penicillin and sulphanilamide shows that these compounds have almost similar activity.

CONCLUSION

The clubbing of sulfa pyrimidine and thiazolidinone has been done successfully into one molecule. Both the moieties have important applications in medicinal use; the produced compounds may be act as good biological compounds.

Acknowledgment

We are thankful to the department of chemistry, Himchandracharya North Gujarat University, Patan, Gujarat (India) for providing the necessary facilities for the research work.

REFERENCES

- [1] Shepherd, R. G; Sulfanilamides and Other p-Aminobenzoic Acid Antagonists, Medicinal Chemistry , edited by A. Burger (Wiley Interscience , Toronto , **1969** , vol.1, p. 255).
- [2] Krupp, M. A and Chatton, M. J; Current Medical Diagnosis and Treatment (Large Medical Publications, California, **1980**).
- [3] Khunt, Ranjan; Datta, Neela; *J. Indian. Chem. Soc.*, **2001**, 78, 47.
- [4] Joshi,H. D; Sawale,A. R; Ingle,R. D and Mane,R. A; *Indian. J. Chem.*, **2000**, 39,967.
- [5] Ingle ,V. S; Sawale,A. R; Ingle,R. D and Mane,R. A; *Indian. J. Chem.*, **2000**, 40,124.
- [6] Patel,J.A; Mistry,B.D and Desai,K.R; *J.Indian.Chem.Soc.*, **2006**, 83,1041.
- [7] Gadre, J.N; Nair, Samita; Chitre, Saurabh; *Indian J Chem.*,**2007**, 46,653.
- [8] Shetgivi,N.P; Chitre, A.D; Kokitkar,S.V; Ghate,S.M; Patil,S.S & Kelaskar,R.C; *Indian.J.Chem*, **2006**, 45B,1308.
- [9] Mochida Pharmaceutical Co. Ltd, Japan Pat 81,127,383 (1981); *Chem Abstr.*, **1982**, 96, 85572.
- [10] Ingram V. M; Biosynthesis of Macromolecules, 2nd edition (Benjamin Menlo Park), p.212 (**1972**).
- [11] Dash,B; Praharaj,S and Mohapatra,P. K; Thiazolidone Derivatives, *J. Indian. Chem. Soc.*, **1981**, LVIII, 1184.
- [12] Patel,H. S and Mistry,H; *J. Phosphorous, Sulfur and Silicon and Related Element*,**2004**, 179, 1085.
- [13] Aboel-Magd A. Abdel-Wahab , Khairy M. Hassan & Samia R. El-Ezbawy, *Indian. J. Chem*, **1979**, 18B, 467.
- [14] Hassan,KH. M; El-Ezbawy, S. R and Abdel-Wahab, A. A; *J. Indian. Chem. Soc.*, **1979**, LVI, 290.
- [15] Hassan,KH. M & Atta,F. M; *Indian. J.Chem* , **1978**, 16B, 1073.
- [16] a) Barry,A. L; The Antimicrobial Susceptibility Test : Principle and Practices, 4th ed., edited by IIuslea and feger (Philadelphia, 180-193 (**1976**) b) Biol. Abstr., **1977**,64, 25183.
- [17] Vogel,A. I; A Textbook of Practical Organic Chemistry, 5th ed., Pearson Education, Ltd., Singapore, pp.883(**2004**).
- [18] El-hashash, M.A; Mahmoud,M.R & Madboli,S.A; *Indian. J Chem.*, **1993**, 32B, 449.
- [19] Bellamy, L. J; The Infrared Spectra of Complex Molecule (John Wiley and Sons, New York, **1954**).